They Announced a Stock Offering One Minute After the Close... Ugh...
On November 17 (Eastern Time), the hottest stock on Wall Street was SELLAS Life Sciences (SLS), a cancer immunotherapy developer.
Before the open, at 7 a.m., word came out that the Phase 3 trial (REGAL) of galinpepimut-S (GPS), a maintenance vaccine for acute myeloid leukemia (AML), had hit its primary endpoint.
The stock, which was at $7.47 the day before, spiked as high as $24.89 intraday, and it closed the regular session up 156.36% at $19.15. In a single day, its market cap swelled by nearly $2.38 billion, from about $1.52 billion to $3.9 billion.
But the investors' cheers went cold just one minute after the regular session ended. At 4:01 p.m., the company announced a plan for a $150 million common stock offering, and around 4:15 p.m. it filed a preliminary prospectus with the offering terms.
Once investors saw that SELLAS had jumped straight into a new share offering on the back of the surge, the stock slid roughly 10-13% in after-hours trading, to the $16.61-$17.15 range.
✦ Relative Price Comparison Over the Last 4 Weeks
SELLAS (SLS), biotech ETF (XBI) and S&P 500 (SPY) regular-session closes, Oct 20, 2026 = 100
Just Five Days Ago They Said "We Have Enough Cash"...
What threw investors off was the timing of the fundraising.
Just five days earlier, on November 12, when it reported Q3 earnings, SELLAS had said that with $134.71 million in cash and cash equivalents as of the end of September, it had 'enough funds to run operations for more than the next 12 months'.
In fact, total liabilities at the end of Q3 came to just $9.29 million, counting accounts payable, accrued expenses and operating lease liabilities ($599,000), and it had no financial borrowings at all.
What's more, SELLAS set up a $150 million ATM with TD Cowen this March and never used it. So investors had a hard time seeing the surprise stock offering announcement coming.
✦ Good to Know
ATM (at-the-market offering)
This offering is 100% new shares, with no 'secondary sale' where existing shareholders sell their holdings. So once it's done, everything raised, minus fees, goes to the company.
J.P. Morgan and TD Cowen are the joint lead managers, and the offering price is set after a book-building round with institutional investors.
The company announced a $150 million offering, but there's also an over-allotment option that lets the underwriters buy up to $22.5 million more within 30 days. If the option is exercised in full, the total size grows to as much as $172.5 million.
Anyway, existing shareholders will be diluted once the offering is done, but the company gets to raise a big sum on favorable terms with the stock up more than 156% in a single day.
Since it had $134.71 million in cash at the end of September, simply adding the $150 million without counting fees and the like, SELLAS would end up with roughly $280 million in cash.
SELLAS does have a lot to spend money on. Its accumulated deficit (the losses piled up so far) stood at $303.09 million at the end of Q3, and the operating loss for Q3 alone was $11.3 million, with R&D spending of $7 million and SG&A of $4.3 million.
So at a point when big money will be needed for the approval application and commercialization prep, and the stock had surged, it looks like the company announced the large stock offering by surprise.
Either way, it's true that investors got blindsided, and it stings.
Was the Phase 3 Result Really Big Enough for a 156% Surge?
The REGAL trial enrolled 126 patients whose acute myeloid leukemia (AML) had relapsed, who were treated again and whose cancer cells could no longer be seen.
Along with patients in second or later complete remission (CR2), whose blood counts also returned to normal, it included patients (CRp2) whose platelet counts had recovered less.
They're all high-risk patients with a big chance of relapse because it's hard for them to get a stem cell (bone marrow) transplant from another person.
✦ Phase 3 (REGAL) Survival Results
126 patients with relapsed acute myeloid leukemia (AML)
A trial that measures survival for a cancer drug has to wait until a set number of patients have died before it can issue a final report card. The results finally came out when the target '80th event' was confirmed on October 28.
Looking at the results, the time that half of the GPS vaccine group survived stretched to 24.0 months, so they lived 9.3 months longer than the comparison group that got existing treatment (14.7 months).
The risk of death over the same period was 41% lower than in the comparison group, too, and the chance of getting this result purely by luck was just 3.5% (p=0.035), so it passed the statistical threshold (under 5%) for recognizing that a drug works.
That's enough to call it a success.
✦ The Supply and Demand Behind the Surge
Short interest is as of the October 30 settlement date
But that alone can't explain the 156% surge that day. The supply and demand picture at the time also seems to have had a big effect on the surge.
That's because, as of the October 30 settlement date, 57.13 million shares, or 28.61% of the float, were sold short.
On the trial success news, buy-to-cover purchases from short sellers rushing to close out their positions poured in, and call option buying, up 522% to 261,202 contracts, flooded in all at once, so the stock seems to have shot up like crazy.
And a good report card from a Phase 3 trial doesn't mean the drug can be sold right away. That's because the strict review process at the United States Food and Drug Administration (FDA) is still ahead.
On top of that, you should note that there are some murky points in this trial data.
✦ Murky Points in This Trial Data
To start, the trial had only 126 patients, which is a small number. And it was run as an 'open-label' study, where patients and doctors both know who got the vaccine instead of mixing in a placebo.
Also, the comparison group patients didn't all get a single standard drug.
Some got no drug and were just monitored, while others got existing cancer drugs (hypomethylating agents, venetoclax and so on), so a mix of treatments was used depending on the treating doctor's choice.
If the comparison group had a high share of patients who were only monitored with no drug, the new drug's effect could look bigger than it really is, so more detail has to come out on what share of patients got each treatment.
So it's too early to be thinking, 'Phase 3 succeeded, so they'll be selling the new drug soon!'
Let's Think About Whether a $3.9 Billion Market Cap Makes Sense
After the surge, SELLAS has a market cap of about $3.9 billion.
Since it's running at a loss, with earnings per share of -$0.20 over the trailing 12 months (a cumulative net loss of $28.1 million for January-September this year), you can't value the current stock price on a P/E basis.
In particular, SELLAS is a clinical-stage company with no product revenue and only R&D costs going out, so the consensus of analysts' earnings estimates isn't clear either.
✦ Valuation and Key Financial Metrics
Based on the November 17, 2026 close
| Metric | Figure | Notes |
|---|---|---|
| Regular-session close / market cap | $19.15 / about $3.90 billion | Shares outstanding: 203.53 million (as of the end of Q3) |
| Size of the planned stock offering | Base $150 million ($172.5 million with the option) | 100% new shares; offering price, share count and completion not yet set |
| Trailing P/E | N/A | Loss over the past 12 months (EPS -$0.20) |
| Forward P/E | N/A | At the stage of targeting a 2027 approval application, so losses continue |
| Cash / total liabilities at the end of Q3 | $134.71 million / about $9.29 million | Financial borrowings $0 (operating lease liabilities $599,000) |
One thing to watch is that shares could keep being issued even after this offering.
In January-September this year, exercises of existing warrants brought in $85.1 million in cash, but shares outstanding grew 32.9%, from 153.1 million at the start of the year to 203.53 million at the end of September.
Add the 8.12 million unexercised warrants, 3.31 million RSUs (restricted stock units) and 2.65 million stock options as of the end of September, and about 14.08 million shares (6.9% of the existing shares outstanding) remain as potential supply.
The unused $150 million ATM limit set up in March is also still open. The company can use it if it decides it's needed.
Let's assume that after the offering is completed, the stock settles somewhere between the November 17 regular-session close ($19.15) and the after-hours price ($16.61).
The base offering alone would put roughly 7.83 million to 9.03 million new shares on the market (3.8-4.4% of the existing 203.53 million shares outstanding).
If the over-allotment option is exercised too, roughly 9.01 million to 10.39 million shares (4.4-5.1%) would come out. Since institutional offerings usually come with a discount, the actual number of shares issued is likely to end up higher than this range.
✦ Analyst Price Target Consensus for SELLAS
Two firms gave price targets; the base price is the November 17 close (Nasdaq regular session)
$35 · +82.8%
Of the 3 firms that gave ratings, 2 rate it a Buy (Maxim Group, Alliance Global Partners) and 1 rates it a Sell (Weiss Ratings).
Wall Street's views on SELLAS are split, but price targets have climbed steeply this year.
Of the three firms that gave ratings, Maxim Group and Alliance Global Partners rate it a Buy, while Weiss Ratings rates it a Sell. As of the first half of this year, Maxim Group and Alliance Global Partners both had price targets around $10.
Through the trial excitement, though, Alliance Global Partners raised its target step by step from $10 to $25 and then $35, and Maxim Group raised its from $10 to $30 and then $40 on the day of the trial announcement.
As a result, the average price target now stands at $37.50 (+95.82% from the current stock price).
Wrapping Up
Let's think about what SELLAS investors should be watching going forward.
✦ Four Things to Watch Ahead
First up is whether this stock offering goes through and what the final offering price is. It'll matter whether the offering actually closes and how big a discount to the closing price the offering price ends up at.
Second is the clinical result for SLS009, the second drug candidate, which will be released at the American Society of Hematology (ASH) on December 14.
Phase 2 data from a trial in acute myeloid leukemia (AML) patients who relapsed after earlier treatment or didn't respond to drugs will be presented that day.
On top of that, a separate Phase 2 trial is underway using SLS009 together with existing drugs for patients newly diagnosed with AML who are starting first treatment.
If preliminary results from this trial, scheduled for Q4, also go well, the investment value of SELLAS could rise further.
Third is the result of the meeting with the FDA and whether the Biologics License Application (BLA) gets filed in the first half of 2027.
It's uncertain whether the FDA will take up a formal review or an accelerated approval path based on open-label Phase 3 data from 126 patients.
If this gets sorted out, SELLAS can file the application in the first half of next year as targeted and take another step toward commercialization.
On the flip side, if the FDA asks for additional data or a supplementary trial, the approval timeline could slip and the cost burden could grow again.
Fourth is how the cash will be used.
If this offering wraps up successfully, SELLAS will be holding around $280 million in cash, and the company's fate could swing on whether it pushes ahead with commercializing on its own or uses the cash in technology transfer or sale talks with a big pharma company.
This isn't investment advice. You know that, right? Let's each protect our own hard-earned money.
That's all for this post. See you next time.
Related posts
- CoreWeave Soars 25%: AI Stock Comparison, P/E 10.9 to 941.7
- Anthropic (ANT) Nasdaq IPO Nov 19: Is It Worth the Price?
- Strategy (MSTR) Cut From MSCI, $8.4B Down, Still Buying BTC?
🌐 Korean version: 임상 3상 성공으로 하루 +156% 폭등한 셀라스(SLS), 장 마감 직후 '유상증자' 기습 발표... 뒤통수가 얼얼하네
🌐 Japanese version: 第3相成功で1日+156%、直後に公募増資を発表したセラス(SLS)
No comments:
No comments yet. Want to leave the first one?
Post a Comment